04/06/2026
From Lab to Leap – how AI Startups are reshaping Life Science
At this year's Sartorius AI Conference 3.0 in Göttingen, Dr. Hendrik Windel, co-founder and CTO of myotwin, and Dr. Lisa Ramirez, neurochemist and project manager at brainQr Therapeutics - two startups that are part of the Life Science Factory - had the opportunity to introduce themselves and demonstrate how they are pushing the boundaries of what is possible in biomedical research.
🫀 myotwin is developing digital twins of the human heart. By combining biological data with AI-based modeling, they create virtual heart systems that allow researchers to simulate diseases and test therapies digitally – reducing reliance on traditional lab experiments and accelerating drug development.
🧠 brainQr Therapeutics is taking a similar approach for the brain. Their work focuses on modelling complex brain proteins and neurological processes, enabling a deeper understanding of diseases and opening up new pathways for targeted therapies.
What both startups have in common:
They shift experimentation from the lab to the digital space, thereby making research faster, more scalable, and more precise.
As an incubator, we at Life Science Factory support startups like these from the early development phase through to growth by providing them with access to infrastructure, expertise, and a strong network spanning science and industry.
Seeing these approaches presented in the context of this year’s theme, “We Built the Brain, Now We Build the Body,” made one thing clear: AI in life sciences is no longer theoretical – it’s already creating tangible impact.
